FDA approves Juvmo (tavapadon), a selective D1/D5 receptor partial agonist, for Parkinson disease based on phase 3 TEMPO trial data.

Time-restricted eating may be a safe and reasonable method for improving disease markers in people with Huntington disease.

An FDA panel supports Galleri, a blood test designed to detect multiple cancer types, despite some concern that the test is not reliable.

Pediatric patients receiving GLP-1 receptor agonist treatment appear to have higher rates of nutritional deficiency.

Multiple-component and multifactorial interventions do not meaningfully improve fall rates among older people compared with usual care.

Patients with atypical Alzheimer disease frequently fail to meet the clinical criteria required to receive targeted anti-amyloid therapies.

Treatment with intravenous inebilizumab is associated with a significantly decreased risk for exacerbations in adults with generalized myasthenia gravis.